MedTrace Logo

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)

NCT05997433 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2024-01-11

No results posted yet for this study

Summary

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of gastric cancer.The researchers collect H.pylori-positive patients who need native therapy. The subjects were randomized to receive7 days and 14 days of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient compliance of each group.

Conditions

  • Helicobacter Pylori Infection

Interventions

PROCEDURE

7days bismuth quadruple

Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days

PROCEDURE

14 days bismuth quadruple

Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days

Sponsors & Collaborators

  • Zibo Maternal and Child Health Hospital

    collaborator UNKNOWN

  • Zaozhuang Municipal Hospital

    collaborator OTHER

  • Binzhou Maternal and Child Health Hospital

    collaborator UNKNOWN

  • Jinxiang County People's Hospital

    collaborator UNKNOWN

  • Linyi Yizhou Hospital

    collaborator UNKNOWN

  • Yantai Penglai Traditional Chinese Medicine Hospital

    collaborator UNKNOWN

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Yanqing Li, Ph.D · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-02
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05997433 on ClinicalTrials.gov